ORNBVH Stock Overview
Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €44.83 |
| 52 Week High | €49.89 |
| 52 Week Low | €36.52 |
| Beta | 0.36 |
| 11 Month Change | -7.92% |
| 3 Month Change | 2.07% |
| 1 Year Change | n/a |
| 33 Year Change | 16.38% |
| 5 Year Change | 13.49% |
| Change since IPO | 193.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORNBVH | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -0.1% |
| 1Y | n/a | -4.0% | 5.5% |
Return vs Industry: Insufficient data to determine how ORNBVH performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORNBVH performed against the UK Market.
Price Volatility
| ORNBVH volatility | |
|---|---|
| ORNBVH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ORNBVH's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ORNBVH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 3,867 | Liisa Hurme | www.orion.fi |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| ORNBVH fundamental statistics | |
|---|---|
| Market cap | €6.26b |
| Earnings (TTM) | €331.70m |
| Revenue (TTM) | €1.43b |
18.9x
P/E Ratio4.4x
P/S RatioIs ORNBVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORNBVH income statement (TTM) | |
|---|---|
| Revenue | €1.43b |
| Cost of Revenue | €573.20m |
| Gross Profit | €856.00m |
| Other Expenses | €524.30m |
| Earnings | €331.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 59.89% |
| Net Profit Margin | 23.21% |
| Debt/Equity Ratio | 27.8% |
How did ORNBVH perform over the long term?
See historical performance and comparison